重症患者静脉碳酸氢钠短缺:中断时间序列分析
该研究为中断时间序列分析,纳入加拿大阿尔伯塔省17个成人ICU在2015年6月1日至2019年12月31日收治的18,865例血pH值小于7.3的成人患者,评估2017年6月8日至10月4日静脉碳酸氢钠短缺及紧急节约措施对治疗与结局的影响。短缺开始后,接受碳酸氢钠治疗的患者比例从29.3%降至21.5%(绝对变化-7.8%,95%CI -12.8%至-2.8%)。短缺期间接受碳酸氢钠者pH≤7.20的比例更高(78.8% vs 69.0%,p<0.01)。在pH≤7.20且未接受碳酸氢钠的亚组中,使用血管升压药的比例增加9.9%(95%CI 2.4%-17.4%),使用连续肾脏替代治疗的比例增加8.6%(95%CI 0.6%-16.6%)。总体人群及各亚组的ICU住院时间或死亡率无变化。
要点
- 2017年静脉碳酸氢钠短缺期间,紧急节约措施使重症酸血症(pH<7.3)患者接受碳酸氢钠的比例从29.3%降至21.5%(绝对变化-7.8%,95%CI -12.8%至-2.8%)。
- 短缺期间接受碳酸氢钠的患者中pH≤7.20者比例更高(78.8% vs 69.0%,p<0.01),提示节约措施下优先用于更严重酸血症。
- 在pH≤7.20且未接受碳酸氢钠的亚组中,使用血管升压药的比例增加9.9%(95%CI 2.4%-17.4%),使用连续肾脏替代治疗的比例增加8.6%(95%CI 0.6%-16.6%)。
- 总体人群及各亚组的ICU住院时间或死亡率均无变化。
适用人群与场景
- 成人(≥18岁)血pH值小于7.3,于2015年6月1日至2019年12月31日收入加拿大阿尔伯塔省17个成人ICU的患者。
诊断标准与关键阈值
- 酸血症定义:血pH值小于7.3。
- 严重酸血症亚组:pH小于或等于7.20。
- 肾功能亚组:肾脏序贯器官衰竭评估(SOFA)评分大于或等于3。
研究设计与关键结果
- 研究类型:中断时间序列分析,数据来源于eCritical Alberta基于人群的ICU登记库,共纳入18,865例入ICU患者。
- 人群特征:中位年龄62岁(IQR 50-71),中位APACHE II评分23(IQR 18-30),女性占39.6%。
- 主要结局:短缺开始后,接受静脉碳酸氢钠治疗的患者比例从29.3%降至21.5%,绝对变化-7.8%(95%CI -12.8%至-2.8%)。
- 短缺期间接受碳酸氢钠者pH≤7.20的比例为78.8%,高于短缺前的69.0%(p<0.01)。
- 在pH≤7.20且未接受碳酸氢钠的亚组中,使用血管升压药的比例增加9.9%(95%CI 2.4%-17.4%),使用连续肾脏替代治疗的比例增加8.6%(95%CI 0.6%-16.6%)。
- 在肾脏SOFA评分≥3且未接受碳酸氢钠的亚组中观察到类似趋势。
- 总体人群及各亚组的ICU住院时间或死亡率无变化。
证据类型、等级与局限
- 证据类型:中断时间序列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,伴随全球静脉碳酸氢钠短缺的紧急节约措施与重症酸血症患者静脉碳酸氢钠使用减少相关,但未伴随生存率或住院时间结局的改变。
- 作者认为,未来的碳酸氢钠研究应聚焦于严重酸血症和/或晚期肾功能不全等亚组。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To examine effects of the 2017 worldwide shortage of IV sodium bicarbonate on outcomes of critically ill adults with acidemia.
DESIGN: Interrupted time-series analysis.
SETTING: Seventeen adult ICUs in Alberta, Canada.
PATIENTS: Adults (≥ 18 yr) with blood pH value of less than 7.3, admitted to study ICUs between June 1, 2015, and 31 December 2019.
INTERVENTIONS: The 2017 sodium bicarbonate shortage occurred between 8 June and October 4, 2017. Our health authority enacted emergency conservation measures during this time.
MEASUREMENTS AND MAIN RESULTS: The main data source was eCritical Alberta, a population-based ICU Registry. The primary outcome was the proportion of patients treated with IV sodium bicarbonate. Outcomes were examined via segmented regression. Among 18,865 admissions, median age was 62 years (interquartile range [IQR] 50-71), median Acute Physiology and Chronic Health Evaluation (APACHE) II was 23 (IQR 18-30), and 39.6% were female. Immediately after start of the shortage, patients treated with bicarbonate decreased from 29.3% to 21.5% (absolute -7.8%; 95% CI, -12.8 to -2.8%). During the shortage bicarbonate recipients more likely had pH less than or equal to 7.20 (78.8% vs. 69.0%, p < 0.01). Subgroup analysis among those with pH less than or equal to 7.20 who did not receive bicarbonate during the shortage suggested increased proportion treated with vasopressors (9.9%; 95% CI, 2.4-17.4%) and continuous renal replacement therapy (8.6%; 95% CI, 0.6-16.6%). Similar trends were observed among those with renal sequential organ failure assessment greater than or equal to 3 who did not receive bicarbonate during the shortage. There was no change in ICU length of stay or mortality in overall population or subgroups.
CONCLUSIONS: Emergency conservation measures that accompanied a worldwide shortage of IV sodium bicarbonate were associated with a reduction in IV sodium bicarbonate use among critically ill patients with acidemia. This was not linked to changes in survival or length of stay outcomes. Future bicarbonate research should focus on subgroups such as those with severe acidemia and/or advanced renal insufficiency.
参考来源
- Leong AY, Soo A, Bond A, et al. An IV Sodium Bicarbonate Shortage in the Critically Ill: An Interrupted Time-Series Analysis. Crit Care Med. 2025. PMID: 40758398. doi:10.1097/CCM.0000000000006813
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。